Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 9/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25925716 | 0.85 | PIK3CA (0.42) | PIK3CAMTORGAKFFAR2MAP3K12 | |
| SCHEMBL25931435 | 0.82 | LRRK2 (0.44) | PIK3CAMTORFFAR2LRRK2SCN10A | |
| SCHEMBL2711884 | 0.79 | PIK3CA (0.44) | PIK3CAMTORGAKFFAR2MAP3K12 | |
| SCHEMBL25930722 | 0.79 | PIK3CA (0.37) | PIK3CAMTORGAKFFAR2MAP3K12 | |
| SCHEMBL2712256 | 0.79 | ALDH1A1 (0.45) | PIK3CAMTORGAKFFAR2LRRK2 | |
| SCHEMBL2710577 | 0.78 | KDM4E (0.46) | PIK3CAMTORLRRK2 | |
| SCHEMBL12235999 | 0.77 | PIK3CA (0.47) | PIK3CAMTORGAKFFAR2MAP3K12 | |
| SCHEMBL23622936 | 0.76 | PIK3CA (0.44) | PIK3CAMTORGAKFFAR2MAP3K12 | |
| SCHEMBL12236672 | 0.76 | PIK3CA (0.45) | PIK3CAMTORGAKFFAR2MAP3K12 | |
| SCHEMBL21513241 | 0.73 | OPRK1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2445886-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 29/4885MTOR 355/4885GAK 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.